About: Remdesivir potently inhibits SARS-CoV-2 in human lung cells and chimeric SARS-CoV expressing the SARS-CoV-2 RNA polymerase in mice

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Remdesivir potently inhibits SARS-CoV-2 in human lung cells and chimeric SARS-CoV expressing the SARS-CoV-2 RNA polymerase in mice Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Remdesivir potently inhibits SARS-CoV-2 in human lung cells and chimeric SARS-CoV expressing the SARS-CoV-2 RNA polymerase in mice
Creator	Baric, Ralph Schäfer, Alexandra Yount, Boyd Cihlar, Tomas Lu, Xiaotao Gully, Kendra Sheahan, Timothy Perry, Jason Babusis, Darius Denison, Mark Feng, Joy Murakami, Eisuke Porter, Danielle Agostini, Maria Brown, Ariane Chappell, James Dinnon Iii, Kenneth Graham, Rachel Leist, Sarah Pruijssers, Andrea Stevens, Laura Bilello, John George, Amelia Gralinksi, Lisa Hughes, Tia Ma, Bin Martinez, David Org, Ardina Pitts, Jared Pont, Venice
Source	BioRxiv; Medline
abstract	Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) emerged in 2019 as the causative agent of the novel pandemic viral disease COVID-19. With no approved therapies, this pandemic illustrates the urgent need for safe, broad-spectrum antiviral countermeasures against SARS-CoV-2 and future emerging CoVs. We report that remdesivir (RDV), a monophosphoramidate prodrug of an adenosine analog, potently inhibits SARS-CoV-2 replication in human lung cells and primary human airway epithelial cultures (EC50 = 0.01 μM). Weaker activity was observed in Vero E6 cells (EC50 = 1.65 μM) due to their low capacity to metabolize RDV. To rapidly evaluate in vivo efficacy, we engineered a chimeric SARS-CoV encoding the viral target of RDV, the RNA-dependent RNA polymerase, of SARS-CoV-2. In mice infected with chimeric virus, therapeutic RDV administration diminished lung viral load and improved pulmonary function as compared to vehicle treated animals. These data provide evidence that RDV is potently active against SARS-CoV-2 in vitro and in vivo, supporting its further clinical testing for treatment of COVID-19.
has issue date	2020-04-27(xsd:dateTime)
bibo:doi	10.1101/2020.04.27.064279
bibo:pmid	32511392
has license	biorxiv
sha1sum (hex)	c558266cf583cc2c375fff8f4870a2e9f7f0ac21
schema:url	https://doi.org/10.1101/2020.04.27.064279
resource representing a document's title	Remdesivir potently inhibits SARS-CoV-2 in human lung cells and chimeric SARS-CoV expressing the SARS-CoV-2 RNA polymerase in mice
has PubMed identifier	32511392
schema:publication	bioRxiv
resource representing a document's body	covid:c558266cf583cc2c375fff8f4870a2e9f7f0ac21#body_text
is schema:about of	named entity 'polymerase' named entity 'cells' named entity 'inhibits' named entity 'human lung' named entity 'Remdesivir' named entity 'SARS-CoV-2' named entity 'EC50' named entity 'pulmonary function' named entity 'EC50' named entity 'Vero E6' named entity 'antiviral effect' named entity 'transcription' named entity 'phenotype' named entity 'RdRp' named entity 'RdRp' named entity 'EC50' named entity 'potency' named entity 'endemic' named entity 'exoribonuclease' named entity 'C57Bl/6' named entity 'SARS-CoV-2 virus' named entity 'apical surface' named entity 'CoV' named entity 'mobile phase' named entity 'weight loss' named entity 'pseudostratified' named entity 'GS-441524' named entity 'epithelium' named entity 'Ashland, MA' named entity 'incubation period' named entity 'methanol' named entity 'replicase' named entity 'endogenous' named entity 'COVID' named entity 'GraphPad Prism' named entity 'body plethysmography' named entity 'viral genome' named entity 'Mice' named entity 'ammonium formate' named entity 'dose-dependent manner' named entity 'SARS-CoV-2' named entity 'non-linear regression' named entity 'broad-spectrum' named entity 'Mice' named entity 'ATP' named entity 'GS-441524' named entity 'EC50' named entity 'positive control' named entity 'viral titer' named entity 'infection' named entity 'epithelial' named entity 'surrogate marker' named entity 'HTS'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software